NCT05457010 2024-06-12
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Arcellx, Inc.
Phase 1 Unknown
Clinical Trials
125 trialsNCT04021368 2024-02-14
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Ryvu Therapeutics SA
Phase 1 Unknown
NCT05641259 2024-02-02
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1 Unknown
NCT06209671 2024-01-17
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Unknown
NCT04599556 2023-12-06
Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy
Zhejiang University
Phase 1 Unknown
NCT06125106 2023-11-09
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
Zhejiang University
Phase 1 Unknown
NCT05716919 2023-10-23
Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule
Machaon Biotherapeutics, Inc.
Phase 1 Unknown
NCT04825496 2023-09-21
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Unknown
NCT03709914 2023-09-15
Pediatric_PK
Nabriva Therapeutics AG
Phase 1 Unknown
NCT06008405 2023-09-06
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05982756 2023-08-09
Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML
Zhongnan Hospital
Phase 1 Unknown
NCT05970822 2023-08-01
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
Biocity Biopharmaceutics Co., Ltd.
Phase 1 Unknown
NCT05226468 2023-07-27
An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia
New Epsilon Innovation Limited
Phase 1 Unknown
NCT05690425 2023-07-24
A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
Biocity Biopharmaceutics Co., Ltd.
Phase 1 Unknown
NCT04763083 2023-07-07
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
NovalGen Ltd.
Phase 1 Unknown
NCT05471323 2023-05-19
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
Guangdong Ruishun Biotech Co., Ltd
Phase 1 Unknown
NCT04471064 2023-05-18
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Phase 1 Unknown
NCT05487651 2023-05-18
ANCHOR2
Athenex, Inc.
Phase 1 Unknown
NCT04356846 2023-05-01
A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 1 Unknown
NCT05697510 2023-04-06
SILTUXILAM
Nantes University Hospital
Phase 1 Unknown
NCT05495035 2023-03-02
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Unknown
NCT05731219 2023-02-16
UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1 Unknown
NCT05727683 2023-02-14
CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Unknown
NCT03533816 2023-02-08
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
University of Kansas Medical Center
Phase 1 Unknown
NCT05679687 2023-01-11
ThisCART19A Bridging to alloHSCT for R/R B-ALL
The First Affiliated Hospital of Soochow University
Phase 1 Unknown
NCT05665114 2023-01-03
Natural Killer(NK) Cell Therapy in r/r AML
Zhejiang University
Phase 1 Unknown
NCT04100187 2022-12-01
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
Kecellitics Biotech Company Ltd
Phase 1 Unknown
NCT05610202 2022-11-09
Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT03855371 2022-11-04
PANDA-T0
Ruijin Hospital
Phase 1 Unknown
NCT05577611 2022-10-13
An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Zhongnan Hospital
Phase 1 Unknown
NCT04684472 2022-09-26
Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies
Sichuan University
Phase 1 Unknown
NCT05489276 2022-08-05
Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05212584 2022-07-06
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
iCell Gene Therapeutics
Phase 1 Unknown
NCT05445765 2022-07-06
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
iCell Gene Therapeutics
Phase 1 Unknown
NCT05426798 2022-06-22
Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05410041 2022-06-08
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies
Beijing Boren Hospital
Phase 1 Unknown
NCT04886206 2022-05-11
ILDA
Nantes University Hospital
Phase 1 Unknown
NCT04709458 2022-05-03
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
Taiga Biotechnologies, Inc.
Phase 1 Unknown
NCT05003141 2022-03-28
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Phase 1 Unknown
NCT05297123 2022-03-28
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid
First Affiliated Hospital Xi'an Jiaotong University
Phase 1 Unknown
NCT04823091 2022-03-16
Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT05277753 2022-03-15
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
Shenzhen Geno-Immune Medical Institute
Phase 1 Unknown
NCT04604691 2022-03-08
Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD)
Seoul National University Hospital
Phase 1 Unknown
NCT05263271 2022-03-02
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05223686 2022-02-04
To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.
Hrain Biotechnology Co., Ltd.
Phase 1 Unknown
NCT03412292 2022-01-19
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)
Maxinovel Pty., Ltd.
Phase 1 Unknown
NCT03823365 2021-12-23
BET2017
A.O. Ospedale Papa Giovanni XXIII
Phase 1 Unknown
NCT04014894 2021-11-12
ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT05020639 2021-09-21
A Study of TQB3820 in Patients With Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT03798509 2021-08-31
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
Hrain Biotechnology Co., Ltd.
Phase 1 Unknown